Barclays upgrades Thermo Fisher to Overweight, raises PT to $550.

Barclays upgrades Thermo Fisher to Overweight, raises PT to $550.

Barclays has upgraded its rating for Thermo Fisher Scientific Inc. (NYSE:TMO) to "Overweight" from "Equal Weight" and raised the price target to $550, according to a recent research report [^NUMBER]. This upgrade reflects the investment bank's bullish view on the company's growth prospects, particularly in the bioprocessing and diagnostics segments.

Thermo Fisher Scientific is a leading provider of laboratory and scientific equipment, with a diverse product portfolio that includes laboratory equipment, scientific analysis equipment, and diagnostics equipment. The company's revenue is primarily derived from product sales (78.5%) and services (21.5%), with significant contributions from North America (53.1%), Europe (25.1%), Asia/Pacific (18.4%), and other regions [^NUMBER].

The upgrade by Barclays comes on the heels of Thermo Fisher Scientific's acquisition of Solventum Corporation's purification and filtration business for $4.0 billion. This transaction aims to expand the company's bioprocessing and adjacent market offerings, with the potential to generate $750 million in revenue by 2025 [^NUMBER]. The acquisition is expected to enhance Thermo Fisher Scientific's product offerings and strengthen its market position, particularly in the bioprocessing sector.

Analysts have been largely optimistic about Thermo Fisher Scientific's prospects. As of September 9, 2025, the average recommendation for the stock among analysts is "Moderate Buy," with a target price of $589.38 [^NUMBER]. Several analysts have recently upgraded the stock, including Scotiabank, UBS Group, and Raymond James Financial, who have raised their price targets to $590.00, $500.00, and $535.00, respectively [^NUMBER].

Despite the positive analyst sentiment, Thermo Fisher Scientific's stock has been trading down in recent sessions, reaching a low of $477.03 on September 10, 2025. The company's earnings for the quarter ending July 23, 2025, were $5.36 EPS, beating the consensus estimate of $5.22. However, the stock's valuation remains relatively high, with a price-to-earnings ratio of 27.59 and a price-to-book ratio of 2.58 [^NUMBER].

In summary, Barclays' upgrade of Thermo Fisher Scientific to "Overweight" and the subsequent raise in the price target reflect the investment bank's confidence in the company's growth prospects, particularly in the bioprocessing and diagnostics segments. The acquisition of Solventum Corporation's purification and filtration business is expected to play a significant role in driving future growth. However, investors should consider the stock's valuation and recent price performance before making any investment decisions.